Anebulo Pharmaceuticals, Inc.
ANEB
$1.05
-$0.02-1.87%
OTC PK
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
2/12/2026
-
Seeking Alpha - Healthcare
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
2/12/2026
-
Business Wire
2/6/2026
-
The Fly
2/6/2026
-
Business Wire
1/29/2026
-
GuruFocus
1/29/2026
-
Business Wire
1/27/2026
-
GuruFocus
1/27/2026
-
TipRanks Financial Blog
1/27/2026
-
Business Wire
1/16/2026
-
Ticker Report
12/26/2025
-
Benzinga
12/23/2025
-
Simply Wall St
12/22/2025
-
GuruFocus
12/22/2025
-
GuruFocus
12/22/2025
-
Business Wire
12/4/2025
-
MarketBeat
11/15/2025
-
Ticker Report
11/13/2025
-
GuruFocus
11/13/2025
-
The Fly
11/13/2025
-
Business Wire
10/25/2025
-
MarketBeat
10/8/2025
-
MarketBeat
9/29/2025
-
Nasdaq News: Markets
9/29/2025
-
Zolmax
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
--
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Thursday, February 12, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 11 and 15 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
--
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
512 598 0931
Address
1017 Ranch Road 620 South
Lakeway, TX 78734
Lakeway, TX 78734
Country
Year Founded
Business Description
Sector
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute...
more